Skip to main content
OpenTrials

Clinical trial condition

EGFR Exon 20 Mutations

Explore clinical trials studying EGFR Exon 20 Mutations. Study availability and eligibility vary by location and protocol.

2 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

EGFR Exon 20 Mutations trial results

Active, Not Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

NCT05364073

Conditions
Advanced Non-Small Cell Lung Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +13 more
Locations
  • ArriVent Investigative Site Prescott, Arizona, United States
  • ArriVent Investigative Site Sacramento, California, United States
  • ArriVent Investigative Site Whittier, California, United States
  • ArriVent Investigative Site Celebration, Florida, United States
View all 42 locations
View Trial Details
Active, Not Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550

Conditions
Advanced Non-Small Cell Lung Cancer, Bronchial Neoplasms, Carcinoma, Bronchogenic, +10 more
Locations
  • Arrivent Investigative Site Daphne, Alabama, United States
  • Arrivent Investigative Site Yuma, Arizona, United States
  • Arrivent Investigative Site Fayetteville, Arkansas, United States
  • Arrivent Investigative Site Beverly Hills, California, United States
View all 208 locations
View Trial Details

Related conditions